We estimate that the Former Interim President and CEO of Arbutus Biopharma Corp ($ABUS), Michael McElhaugh, received a compensation of $3,578,150 in 2025. This is an increase of 41.03% from an estimated $2,110,083 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 14, 2026. Note that parsing errors may occur.
You can track $ABUS on Quiver Quantitative's $ABUS stock dashboard.
$ABUS Stock Hedge Fund Activity
We have seen 74 institutional investors add shares of $ABUS Stock stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAR1 CAPITAL MANAGEMENT, LLC added 2,511,883 shares (+86.5%) to their portfolio in Q4 2025, for an estimated $12,082,157
- MORGAN STANLEY added 2,252,164 shares (+9.2%) to their portfolio in Q4 2025, for an estimated $10,832,908
- FOURSIXTHREE CAPITAL LP removed 1,978,975 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,518,869
- STATE STREET CORP added 1,809,893 shares (+44.2%) to their portfolio in Q4 2025, for an estimated $8,705,585
- TWO SEAS CAPITAL LP added 1,597,897 shares (+14.5%) to their portfolio in Q4 2025, for an estimated $7,685,884
- FOURWORLD CAPITAL MANAGEMENT LLC removed 1,020,910 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,910,577
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 890,898 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,285,219
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ABUS Stock Analyst Ratings
Wall Street analysts have issued reports on $ABUS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 11/14/2025
To track analyst ratings and price targets for $ABUS Stock, check out Quiver Quantitative's $ABUS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
